Coeptis Therapeutics (COEP) Competitors $13.01 +0.58 (+4.67%) Closing price 04:00 PM EasternExtended Trading$13.20 +0.20 (+1.50%) As of 07:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesSEC FilingsShort InterestTrendsBuy This Stock COEP vs. JBIO, ALLO, FENC, ENGN, TNXP, PRQR, IMMP, SGMT, HUMA, and AVTEShould you be buying Coeptis Therapeutics stock or one of its competitors? The main competitors of Coeptis Therapeutics include Jade Biosciences (JBIO), Allogene Therapeutics (ALLO), Adherex Technologies (FENC), enGene (ENGN), Tonix Pharmaceuticals (TNXP), ProQR Therapeutics (PRQR), Prima BioMed (IMMP), Sagimet Biosciences (SGMT), Humacyte (HUMA), and Aerovate Therapeutics (AVTE). These companies are all part of the "pharmaceutical products" industry. Coeptis Therapeutics vs. Its Competitors Jade Biosciences Allogene Therapeutics Adherex Technologies enGene Tonix Pharmaceuticals ProQR Therapeutics Prima BioMed Sagimet Biosciences Humacyte Aerovate Therapeutics Jade Biosciences (NASDAQ:JBIO) and Coeptis Therapeutics (NASDAQ:COEP) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, media sentiment, risk, analyst recommendations, earnings, institutional ownership, valuation and dividends. Do institutionals & insiders hold more shares of JBIO or COEP? 13.9% of Coeptis Therapeutics shares are held by institutional investors. 24.9% of Jade Biosciences shares are held by company insiders. Comparatively, 24.3% of Coeptis Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Is JBIO or COEP more profitable? Jade Biosciences' return on equity of -51.96% beat Coeptis Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Jade BiosciencesN/A -51.96% -47.65% Coeptis Therapeutics N/A -201.73%-108.46% Which has better valuation and earnings, JBIO or COEP? Coeptis Therapeutics is trading at a lower price-to-earnings ratio than Jade Biosciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioJade BiosciencesN/AN/A-$69.63M-$30.33-0.25Coeptis TherapeuticsN/AN/A-$10.88M-$5.80-2.24 Do analysts rate JBIO or COEP? Jade Biosciences currently has a consensus target price of $16.00, suggesting a potential upside of 107.79%. Given Jade Biosciences' stronger consensus rating and higher possible upside, analysts clearly believe Jade Biosciences is more favorable than Coeptis Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Jade Biosciences 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00Coeptis Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has more risk & volatility, JBIO or COEP? Jade Biosciences has a beta of 1.04, indicating that its stock price is 4% more volatile than the S&P 500. Comparatively, Coeptis Therapeutics has a beta of -0.57, indicating that its stock price is 157% less volatile than the S&P 500. Does the media favor JBIO or COEP? In the previous week, Jade Biosciences and Jade Biosciences both had 2 articles in the media. Coeptis Therapeutics' average media sentiment score of 1.92 beat Jade Biosciences' score of 1.33 indicating that Coeptis Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Jade Biosciences 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Coeptis Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive SummaryJade Biosciences beats Coeptis Therapeutics on 8 of the 12 factors compared between the two stocks. Get Coeptis Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for COEP and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding COEP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart COEP vs. The Competition Export to ExcelMetricCoeptis TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$59.92M$3.20B$5.86B$10.15BDividend YieldN/A2.30%5.68%4.59%P/E Ratio-2.2421.1774.5225.93Price / SalesN/A473.02539.62123.65Price / CashN/A46.6837.5660.44Price / Book8.089.6112.166.29Net Income-$10.88M-$53.29M$3.28B$270.77M7 Day Performance6.03%0.29%0.98%3.36%1 Month Performance16.37%8.91%7.20%6.41%1 Year Performance244.00%13.14%63.06%28.26% Coeptis Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)COEPCoeptis Therapeutics0.9097 of 5 stars$13.01+4.7%N/A+236.1%$59.92MN/A-2.242Positive NewsJBIOJade Biosciences2.7084 of 5 stars$7.62-3.5%$16.00+110.0%N/A$248.62MN/A-0.2520ALLOAllogene Therapeutics3.0308 of 5 stars$1.12-0.9%$8.44+654.0%-59.8%$248.51M$20K-1.01310FENCAdherex Technologies2.5167 of 5 stars$8.91+0.5%$13.33+49.6%+71.7%$247.79M$47.54M-21.2110Positive NewsENGNenGene2.6362 of 5 stars$4.80+3.9%$23.29+385.1%-9.6%$245.28MN/A-2.9131Trending NewsEarnings ReportAnalyst ForecastShort Interest ↑Analyst RevisionTNXPTonix Pharmaceuticals3.4065 of 5 stars$27.66-6.6%$70.00+153.1%+107.9%$242.58M$10.09M-0.7050Gap DownPRQRProQR Therapeutics2.6041 of 5 stars$2.29+1.8%$8.00+249.3%+18.4%$240.93M$20.46M-4.98180Short Interest ↑IMMPPrima BioMed1.4526 of 5 stars$1.64+1.9%$7.00+326.8%-35.9%$240.74M$5.14M0.002,021News CoverageSGMTSagimet Biosciences3.2196 of 5 stars$7.36-2.0%$25.67+248.7%+87.2%$239.35M$2M-4.028HUMAHumacyte3.0429 of 5 stars$1.51-2.6%$9.75+545.7%-73.6%$239.14M$818K-3.36150Positive NewsAVTEAerovate TherapeuticsN/A$7.90-2.2%N/A-88.7%$228.98MN/A-2.6420Positive NewsHigh Trading Volume Related Companies and Tools Related Companies Jade Biosciences Alternatives Allogene Therapeutics Alternatives Adherex Technologies Alternatives enGene Alternatives Tonix Pharmaceuticals Alternatives ProQR Therapeutics Alternatives Prima BioMed Alternatives Sagimet Biosciences Alternatives Humacyte Alternatives Aerovate Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:COEP) was last updated on 9/12/2025 by MarketBeat.com Staff From Our PartnersForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredIRS Wants Another Check on Sept 15th—What If You Could Keep It Instead?On September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredDo NOT Day Trade (Do THIS instead)Forget day trading (especially in markets like these). Trade OVERNIGHT instead! I've uncovered a shockin...Monument Traders Alliance | SponsoredCollege grad makes $64,000 a monthIt's easy to feel like you've missed out on the biggest stock market boom of the century. But if you want t...Stansberry Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredAlert: Prepare for Trump's Dollar OverhaulPresident Trump just signed a game-changing law… That could soon upgrade the U.S. dollar in your checking a...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Coeptis Therapeutics Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Coeptis Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
